1.08
1.08 (0%)
As of Feb 14, 2025
Akari Therapeutics Plc [AKTX]
Source:
Company Overview
Akari Therapeutics Plc is a clinical-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases involving the complement component 5 (“C5”) and leukotriene B4 (“LTB4”) pathways.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | (646) 350-0702 |
| Industry | manufacturing |
| CEO | Rachelle Jacques |
| Website | akaritx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-16.8 |
| Net Income | $-10 |
| Net Cash | $-9.4 |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -110.1% |
| Profit as % of Stockholder Equity | 4,370.3% |
Management Effectiveness
| Return on Equity | 4,370.3% |
| Return on Assets | -229.8% |
| Turnover Ratio | 0% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $4.4 |
| Total Liabilities | $4.6 |
| Operating Cash Flow | $-16.4 |
| Investing Cash Flow | |
| Financing Cash Flow | $7 |
